141 related articles for article (PubMed ID: 36719606)
1. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
Deerochanawong C; Krittayaphong R; Romano JGU; Rhee NA; Permsuwan U
Diabetes Ther; 2023 Mar; 14(3):531-552. PubMed ID: 36719606
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Shah D; Risebrough NA; Perdrizet J; Iyer NN; Gamble C; Dang-Tan T
Clinicoecon Outcomes Res; 2018; 10():791-803. PubMed ID: 30532570
[TBL] [Abstract][Full Text] [Related]
3. Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
Clinicoecon Outcomes Res; 2022; 14():487-498. PubMed ID: 35909499
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of transcatheter aortic valve implantation versus surgery in severe aortic stenosis patients with intermediate surgical risk in Thailand.
Permsuwan U; Yoodee V; Buddhari W; Wongpraparut N; Thonghong T; Cheewatanakornkul S; Meemook K; Sakiyalak P; Duangpakdee P; Yadee J
J Geriatr Cardiol; 2022 Nov; 19(11):822-832. PubMed ID: 36561052
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2018 Oct; 18(5):405-413. PubMed ID: 29926351
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility and Cost-Effectiveness Analysis of Spinal Cord Stimulation for Chronic Refractory Pain in the Context of Developing Country.
Zinboonyahgoon N; Saengsomsuan N; Chaikittiporn N; Wangnamthip S; Kositamongkol C; Phisalprapa P
Pain Physician; 2023 Jan; 26(1):69-79. PubMed ID: 36791296
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.
Deerochanawong C; Vareesangthip K; Piyayotai D; Thongsuk D; Pojchaijongdee N; Permsuwan U
Diabetes Ther; 2021 Jul; 12(7):1947-1963. PubMed ID: 34106450
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
Krittayaphong R; Permsuwan U
Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
11. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction.
Krittayaphong R; Yadee J; Permsuwan U
Clinicoecon Outcomes Res; 2019; 11():767-777. PubMed ID: 31824183
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
Roussel R; Martinez L; Vandebrouck T; Douik H; Emiel P; Guery M; Hunt B; Valentine WJ
J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
15. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
17. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
Xie W; Song Y; Qin X; Jin P
Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
[TBL] [Abstract][Full Text] [Related]
19. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]